NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$1.03M, compared with -$5.51M a year earlier. Trailing-twelve-month EBITDA was -$23.33M.
Context
- EBITDA amounted to 2270.0% of revenue in FY2025.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of -$17.4M (+37.4%) for the fiscal year ending Dec 2026, a step up from the -15.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$1.03M-191.2% QoQ
- Last fiscal yearDec 2025
- -$27.81M-15.7% YoY
- LTMMar 2026
- -$23.33M-0.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +81.3% | +76.2% | -5.1 pp |
| 1 year | -15.7% | +37.4% | +53.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (27.81M) USD
- Year-over-year change
- -15.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (27.81M) | -15.7% |
| FY2024 | 2024-12-31 | (24.04M) | +19.9% |
| FY2023 | 2023-12-31 | (30.03M) | +24.5% |
| FY2022 | 2022-12-31 | (39.75M) | +57.3% |
| FY2021 | 2021-12-31 | (93.04M) | — |
EBITDA vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's LTM Mar 2026 EBITDA of -$23.33M is the 5th highest of the 9 companies compared; the peer median is -$29.11M.
- Its year-over-year change of -0.3% is the 4th highest of 9, against a peer median of -25.0%.
- EBITDA amounts to 1017.5% of revenue for NRXP, versus a peer median of 104.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$10.87M | -9.4% | — | 769.0% | |
| LTM Mar 2026 | -$15.84M | +57.4% | — | 48.4% | |
| LTM Mar 2026 | -$18.95M | -40.5% | — | — | |
| LTM Jun 2026 | -$22.02M | +66.8% | — | 104.8% | |
| LTM Mar 2026 | -$23.33M | -0.3% | — | 1017.5% | |
| LTM Mar 2026 | -$36.2M | +34.4% | — | — | |
| LTM Mar 2026 | -$62.08M | -482.8% | — | 18634.1% | |
| LTM Mar 2026 | -$89.9M | -1211.1% | — | — | |
| LTM Mar 2026 | -$147.92M | -653.3% | — | 97.9% | |
| Peer median (excluding NRXP) | -$29.11M | -25.0% | — | 104.8% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1.23M |
| Cost of Revenue | 2K | 4K | 5K | 5K | 505K |
| Gross Profit | (2K) | (4K) | (5K) | (5K) | 720K |
| Gross Margin | — | — | — | — | 58.8% |
| Research & Development | 20.26M | 17.03M | 13.37M | 6.2M | 3.78M |
| Selling, General & Admin | 74.94M | 27.3M | 14.21M | 13.5M | 13.06M |
| Operating Expenses | 95.2M | 44.33M | 27.58M | 19.7M | 16.94M |
| Depreciation & Amortization | 2K | 4K | 5K | 5K | 143K |
| EBITDA | (93.04M) | (39.75M) | (30.03M) | (24.04M) | (27.81M) |
| EBITDA Margin | — | — | — | — | -2270.0% |
| Operating Income | (95.2M) | (44.34M) | (27.59M) | (19.7M) | (16.22M) |
| Operating Margin | — | — | — | — | -1324.4% |
| Interest Income | 18 | 249K | 494K | 44K | 12K |
| Interest Expense | 18K | 0 | 120K | 1.08M | 671K |
| Other Income / Expenses | 2.14M | 4.58M | (2.56M) | (5.42M) | (12.4M) |
| Income Before Tax | (93.06M) | (39.75M) | (30.15M) | (25.13M) | (28.62M) |
| Pre-Tax Margin | — | — | — | — | -2336.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (93.06M) | (39.75M) | (30.15M) | (25.13M) | (28.62M) |
| Net Margin | — | — | — | — | -2336.5% |
| EPS (Basic) | (7.44) | (0.60) | (3.98) | (2.39) | (1.34) |
| EPS (Diluted) | (7.44) | (0.60) | (3.98) | (2.39) | (1.34) |
| Weighted Avg Shares | 46.92M | 65.77M | 7.58M | 10.52M | 21.4M |
| Weighted Avg Shares (Diluted) | 46.92M | 65.77M | 7.58M | 10.52M | 21.4M |
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.